The U.K.’s Supreme Court has ruled against Kirkland & Ellis client Regeneron Pharmaceuticals, concluding a lengthy legal battle over antibody patents in the English courts.

The court ruled on Wednesday by a 4-1 majority that two of Regeneron’s patents were invalid in the U.K. on grounds of “insufficiency”, stating that the firm was “claiming a monopoly which was far wider than its contribution to the art”, a press summary released by the court said.